(Q34547893)

2 August 2017

1 reference

title

Topical immunomodulators--progress towards treating inflammation, infection, and cancer (English)

1 reference

2 August 2017

U R Hengge

1

1 reference

2 August 2017

B Benninghoff

series ordinal

2

1 reference

2 August 2017

T Ruzicka

series ordinal

3

1 reference

2 August 2017

M Goos

series ordinal

4

1 reference

2 August 2017

1 October 2001

1 reference

Lancet Infectious Diseases

2 August 2017

1 reference

2 August 2017

1

1 reference

2 August 2017

189-198

1 reference

2 August 2017

3

1 reference

The instructive role of innate immunity in the acquired immune response

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Immunomodulatory agents for prophylaxis and therapy of infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Recalcitrant viral warts treated by diphencyprone immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Natural history of warts. A two-year study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Imiquimod 5% cream (Aldara).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Cytokine induction by the immunomodulators imiquimod and S-27609

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Imiquimod, a topical immune response modifier, induces migration of Langerhans cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Epidemiology of genital human papillomavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Papillomaviruses and human oncogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Antiviral therapy for human papillomaviruses: rational and prospects.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Immunological events in regressing genital warts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Treatment of genital warts with an immune-response modifier (imiquimod).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGF beta 1/IFN beta cytokine pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Decline of infectious skin manifestations in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Communication: papillomavirus DNA in basal cell carcinomas of immunocompetent patients: an accidental association?TITLE.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

The presence of antibodies against virus-like particles of epidermodysplasia verruciformis-associated humanpapillomavirus type 8 in patients with actinic keratoses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Imiquimod 5% cream in the treatment of Bowen's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Lip papillomatosis in immunodeficiency: therapy with imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Imiquimod therapy for molluscum contagiosum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Potentiating effect of imiquimod in the treatment of verrucae vulgares in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900095-0

7 January 2021

10.1016/S1473-3099(01)00095-0

Identifiers

DOI

1 reference

2 August 2017

1 reference